E-Paper
GlaxoSmith set to manufacture 60 mn doses of Novavax Covid-19 vaccine for UK
The British pharmaceutical company will provide the fill-finish capacity -- putting the vaccine into vials and packaging -- for the Novavax shot at its Barnard Castle site in Durham, England, Glaxo said in a statement Monday.
GlaxoSmithKline Plc is set to manufacture as many as 60 million U.K. doses of a Covid-19 vaccine from Novavax Inc. as the government looks to shore up supplies amid tensions with the European Union.
The British pharmaceutical company will provide the fill-finish capacity -- putting the vaccine into vials and packaging -- for the Novavax shot at its Barnard Castle site in Durham, England, Glaxo said in a statement Monday. Novavax is expected to apply for U.K. approval of its vaccine in the second quarter, with production at the Glaxo plant starting as early as May.
The drug substance for the shot is also being manufactured in the northeast of England by Fujifilm Diosynth Biotechnologies U.K. Ltd. The deal was put together by the U.K. government’s Vaccine Taskforce, which agreed to purchase 60 million doses from Novavax last year.
The agreement has the potential to reduce the U.K.’s reliance on overseas vaccine supplies amid a spat with the EU over exports. The bloc has fallen behind peers in vaccination rates, inoculating about 10% of its population, compared with 45% in the U.K. and about 28% in the U.S., according to the Bloomberg vaccine tracker. EU leaders gave their guarded support to plans to restrict vaccine exports last week after it emerged the bloc had sent more shots to the rest of the world than to its own residents.
Vaccinated Britain Is About to Face Its Biggest Covid Test Yet
Glaxo’s investment “shows the strength of U.K. manufacturing and will further boost our vaccine rollout,” Prime Minister Boris Johnson said in a statement. “We remain on track to offer a first jab to all over 50s by April 15, and all adults by the end of July.”
Novavax’s shot was found to be 96.4% effective against mild, moderate and severe symptoms of the disease in a final analysis of its late-stage U.K. trial released earlier this month. The company also released final results from a mid-stage trial in South Africa that showed the vaccine was 55.4% effective against a variant circulating there that’s been shown to partially elude the protection of some shots.
The Glaxo-Novavax partnership is the latest effort to pair vaccine front-runners with big pharmaceutical companies to help boost production capacity. Glaxo also announced last month that it was supporting the manufacture of up to 100 million doses of a Covid-19 vaccine from Germany’s CureVac NV.
For more articles like this, please visit us at bloomberg.com
©2021 Bloomberg L.P.
